IRCT20200420047147N1招募中2 期
Evaluation the efficacy and safety of Sitagliptin administration in patients with COVID-19
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 84
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 no limit（—）
- 性别
- All
入选标准
- •Patients who diagnosed with COVID-19 by RT-PCR test
- •Oxygen saturation less than 93%
- •Age more than 18 years old
- •To sign the informed consent form
排除标准
- •Chronic kidney disease
- •Acute kidney injury
- •Chronic liver disease
- •pregnancy or breastfeeding
- •Pancreatitis
- •Allergy to Sitagliptin
- •Pemphigus disease history
研究者
相似试验
招募中
不适用
The evaluation of the efficacy of sitagliptin for NASH/NAFLD patients-a multicenter open-label studyJPRN-UMIN000005349Kyoto Prefectural University of Medicine, Department of Gastroenterology and Hepatology50
已完成
不适用
Comparison of efficacy and safety of sitagliptin or ipragliflozin in type 2 diabetic patients with insulin therapyType 2 diabetesJPRN-UMIN000014139Yokohama City University70
招募中
3 期
Evaluation of the effectiveness of sitagliptin on metabolic factors and liver enzymesIRCT20191209045671N2Semnan University of Medical Sciences60
尚未招募
4 期
A clinical study to understand the combined effects ofSitagliptin & metformin, in comparison to Glimepiride & metformin treatment in type 2 diabetes patientsCTRI/2024/04/065877Dr Keerthi Rajan M
已完成
2 期
Sitagliptin and Pioglitazon effects in the treatment of diabetesIRCT2015061619554N4Vice chancellor for research; Zanjan University of Medical Sciences160